Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE S IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte S is an electrolyte and fluid replenisher. It provides water and essential electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) to restore and maintain extracellular fluid volume and electrolyte balance. Acetate and gluconate are metabolized to bicarbonate, serving as bicarbonate precursors to help correct metabolic acidosis.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
FDA: Replacement of extracellular fluid and electrolytes in patients with fluid and electrolyte deficits, maintenance of fluid and electrolyte balance during surgery or in postoperative patients.,Off-label: Treatment of metabolic acidosis, correction of electrolyte imbalances.
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Intravenous administration, typical adult dose is 500-1000 m L per hour, adjusted based on clinical status and electrolyte needs.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
The terminal elimination half-life for the individual electrolytes varies: Sodium has a half-life of approximately 2-4 hours depending on hydration and renal function; potassium has a half-life of 5-7 hours in normal renal function; magnesium has a half-life of 24-72 hours; calcium has a half-life of 3-6 hours. Clinically, the half-life is prolonged in renal impairment, necessitating dose adjustment.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Acetate and gluconate are metabolized via the tricarboxylic acid (TCA) cycle primarily in the liver, producing bicarbonate; acetate is also metabolized peripherally. Sodium, potassium, magnesium, and chloride are excreted renally with minimal hepatic metabolism.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
The electrolytes in ISOLYTE S are primarily excreted via renal elimination. Sodium and chloride are almost entirely excreted by the kidneys, with minimal biliary or fecal elimination (<2%). Potassium is predominantly excreted renally (90%), with approximately 10% eliminated via feces. Magnesium and calcium are mainly excreted in urine (70-80% for magnesium, 20-30% for calcium) with some biliary/fecal excretion. Acetate and gluconate are metabolized to bicarbonate and excreted renally.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Minimal protein binding for most electrolytes: sodium (<5%), potassium (<5%), chloride (<5%), and magnesium (20-30% to albumin). Calcium is 40-50% bound to albumin and other proteins. Acetate and gluconate are not protein bound.
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
Sodium: Vd of 0.25-0.35 L/kg, reflecting distribution primarily in extracellular fluid. Potassium: Vd of 0.4-0.6 L/kg, distributed in both intracellular and extracellular fluid. Magnesium: Vd of 0.5-0.8 L/kg. Calcium: Vd of 0.2-0.3 L/kg. These values indicate that electrolytes distribute widely but predominantly in various body compartments.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Bioavailability is 100% for all components when administered intravenously. For oral administration (not applicable here), bioavailability would vary, but for IV formulation, complete bioavailability is assumed.
100% intravenous; not administered by other routes.
For GFR <30 m L/min, use with caution and monitor electrolytes; dose reduction may be required based on serum potassium and other electrolytes.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalance.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Pediatric dosing is weight-based: 20-30 m L/kg as a single dose, then titrate based on clinical response and electrolyte levels.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Geriatric patients: use lower initial doses (e.g., 250-500 m L over 2-4 hours) and monitor for fluid overload and electrolyte disturbances due to decreased renal function.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
None.
Not applicable; no FDA boxed warning exists for this product.
Risk of fluid overload and congestive heart failure in patients with renal impairment or cardiac disease.,Electrolyte disturbances: hypernatremia, hyperkalemia, hypermagnesemia, hyperchloremia, acidosis or alkalosis.,Use with caution in patients with severe renal impairment, liver disease, or conditions predisposing to electrolyte imbalances.,Avoid rapid infusion in patients with increased intracranial pressure.
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Hyperkalemia (elevated potassium levels).,Hypernatremia (elevated sodium levels).,Hypermagnesemia (elevated magnesium levels).,Acute renal failure with oliguria or anuria.,Hypersensitivity to any component.
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
No specific food interactions. Monitor sodium and fluid intake in patients with hypertension, heart failure, or renal impairment.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
FDA pregnancy category C. No well-controlled studies in pregnant women. Use only if clearly needed. No specific fetal risks known; risk-benefit assessment required.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Compatible with breastfeeding. ISOLYTE S is an electrolyte solution with no known excretion into breast milk; components are normal plasma constituents. M/P ratio not applicable.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
No specific dose adjustments required during pregnancy. Dosing based on clinical assessment of fluid and electrolyte deficits; physiological changes in pregnancy may necessitate adjustments in infusion rate and volume.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
ISOLYTE S is a balanced electrolyte solution for maintenance and replacement therapy. Contains acetate and gluconate as bicarbonate precursors; avoid in patients with severe metabolic alkalosis or hyperkalemia. Use with caution in renal impairment, heart failure, or edema. Monitor serum electrolytes, acid-base balance, and renal function. Do not administer simultaneously with blood products via same IV line due to risk of hemolysis.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
This solution is used to replace fluids and electrolytes in your body.,Tell your doctor if you have kidney disease, heart failure, or fluid retention.,Report any swelling, shortness of breath, or irregular heartbeat.,Do not drink alcohol while receiving this treatment.,Follow any dietary restrictions as advised by your healthcare provider.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE S IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE S IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte S is an electrolyte and fluid replenisher. It provides water and essential electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) to restore and maintain extracellular fluid volume and electrolyte balance. Acetate and gluconate are metabolized to bicarbonate, serving as bicarbonate precursors to help correct metabolic acidosis.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE S IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE S IN PLASTIC CONTAINER is: Intravenous administration, typical adult dose is 500-1000 m L per hour, adjusted based on clinical status and electrolyte needs.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE S IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE S IN PLASTIC CONTAINER is classified as Category C. FDA pregnancy category C. No well-controlled studies in pregnant women. Use only if clearly needed. No specific fetal risks known; risk-benefit assessment required.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.